Hematopoietic cell transplantation (HCT)-related concerns at the time of hospital discharge predict increases in depression but not in anxiety, a study presented at the BMT Tandem Meetings 2016 in Honolulu, Hawaii, has shown.1
Although patient-reported outcomes have become increasingly more important to the daily care of HCT patients, there are limited data on the impact of transplant-related concerns on quality of life.
For the study, researchers enrolled 195 patients who underwent HCT, of which 49% received an autologous HCT and 51% received an allogeneic HCT. Participants completed questionnaires that evaluated their anxiety, depression, quality of life, and transplant-related concerns at hospital discharge, day 90, and day 180.
Results showed no differences in concerns between autologous HCT and allogeneic HCT at hospital discharge (P>.05), but patients who underwent allogeneic HCT reported significantly more concerns at day 90 (P<.05) than those who received autologous HCT.
Researchers found that transplant-related concerns at hospital discharge predicted increases in depression from hospital discharge to day 90 (P<.05); however, they did not predict changes in depression from hospital discharge to day 180 or changes in anxiety to day 90 or day 180 (all P>.05).
The study also demonstrated that particular concerns regarding retaining one’s job, blurry eyesight, trouble concentrating, and reduced libido predicted increased in depression for hospital discharge to day 90 (P<.05).
“These findings highlight the importance of assessing patient concerns regarding HCT, particularly at hospital discharge, and emphasize the importance of performing large prospective clinical research on quality of life-related issues in HCT-recipients,” the authors conclude.
Barata A, Jim H, Martino R, et al. Transplant-related concerns at hospital discharge predict increases in depression. Poster presented at: BMT Tandem Meetings 2016; February 18-22, 2016; Honolulu, HI.